|
Session 128
Poster Abstracts
ART: Treatment-experienced Patients
Monday, 1-4 pm
Room: Hall B |
| 788 |
48-Week Results from BENCHMRK-1, a Phase III Study of Raltegravir in Patients Failing ART with Triple-class Resistant HIV-1
David Cooper*1, J Gatell2, J Rockstroh3, C Katlama4, P Yeni5, A Lazzarin6, X Xu7, R Isaacs7, H Teppler7, B Y Nguyen7, and the BENCHMRK-1 Study Group
1Univ of New South Wales, Sydney, Australia; 2Univ of Barcelona, Spain; 3Univ of Bonn, Germany; 4Hosp Pitie-Salpetriere, Paris, France; 5Hosp Bichat-Claude Bernard, Paris, France; 6San Raffaele Sci Inst, Milan, Italy; and 7Merck Res Labs, West Point, PA, US |
| 789 |
48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir in Patients Failing ART with Triple-class Resistant HIV
Roy Steigbigel*1, P Kumar2, J Eron3, M Schechter4, M Markowitz5, M Loutfy6, J Zhao7, R Isaacs6, B Y Nguyen7, H Teppler7, and the BENCHMRK-2 Study Group
1State Univ of New York at Stony Brook, US; 2Georgetown Univ Med Ctr, Washington, DC, US; 3Univ North Carolina at Chapel Hill, US; 4Federal Univ of Rio de Janeiro, Brazil; 5Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US; 6Univ of Toronto, Canada; and 7Merck Res Labs, West Point, PA, US |
| 790 |
DUET-1: Week-48 Results of a Phase III Randomized Double-blind Trial to Evaluate the Efficacy and Safety of TMC125 vs Placebo in 612 Treatment-experienced HIV-1-infected Patients
Richard Haubrich*1, P Cahn2, B Grinsztejn3, J Lalezari4, J Madruga5, A Mills6, M Peeters7, J Vingerhoets7, K Iveson8, G De Smedt7, and on behalf of the DUET-1 study group
1Univ of California, San Diego, US; 2Hosp Juan A Fernandez and Fndn Huesped, Buenos Aires, Argentina; 3Inst de Pesquisa Clinica Evandro Chagas, FIOCRUZ, Brazil; 4Quest Clinical Res, San Francisco, CA, US; 5Ctr de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; 6Private Practice, Los Angeles, CA, US; 7Tibotec BVBA, Mechelen, Belgium; and 8Tibotec, Inc, Yardley, PA, US |
| 791 |
DUET-2: Week-48 Results of a Phase III Randomized Double-blind Trial to Evaluate the Efficacy and Safety of TMC125 vs Placebo in 591 Treatment-experienced HIV-1-infected Patients
Margaret Johnson*1, T Campbell2, B Clotet3, C Katlama4, A Lazzarin5, W Towner6, M Peeters7, J Vingerhoets7, S Bollen7, G De Smedt7, and on behalf of the DUET-2 study group
1Royal Free Hosp, London, UK; 2Univ of Colorado Hlth Sci Ctr, Denver, US; 3Hosp Unive Germans Trias i Pujol and irsiCaixa Fndn, Barcelona, Spain; 4Hosp Pitie-Salpetriere, Paris, France; 5San Raffaele Univ, Milan, Italy; 6Kaiser Permanente, Los Angeles, CA, US; and 7Tibotec BVBA, Mechelen, Belgium |
| 792 |
Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Treatment-experienced Patients Infected with CCR5-Tropic HIV-1: 48-Week Combined Analysis of the MOTIVATE Studies
David Hardy*1, J Reynes2, I Konourina3, D Wheeler4, S Moreno5, E van der Ryst3, W Towner6, A Horban7, H Mayer8, and J Goodrich8
1David Geffen Sch of Med, Univ of California, Los Angeles, US; 2Univ Hosp of Montpellier, France; 3Pfizer Global R&D, Sandwich, UK; 4Infectious Diseases Physicians, Inc, Annandale, VA, US; 5Hosp Ramon y Cajal, Madrid, Spain; 6Kaiser Permanente, Los Angeles, CA, US; 7Szpital Zakazny Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland; and 8Pfizer Global R&D, New London, CT, US |
| 793 |
24-Week Data from Study AVX-201: A Prospective, Randomized, Double-blind, Dose-ranging Phase IIb Study of Apricitabine in Treatment-experienced Patients with M184V and NRTI Resistance
Pedro Cahn*1, J Altclas2, M Martins3, M Losso4, I Cassetti5, S Cox6, D Cooper7, and the AVX-201 study group
1Fndn Huesped, Buenos Aires, Argentina; 2Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina; 3Inst Oulton, Cordoba, Argentina; 4Hosp JM Ramos Mejia, Buenos Aires, Argentina; 5Helios Salud, Buenos Aires, Argentina; 6Avexa Ltd, Melbourne, Australia; and 7Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, Australia |
| 794 |
Pharmacokinetics and Potent Anti-HIV-1 Activity of Amdoxovir plus Zidovudine in a Randomized Double-blind Placebo-controlled Study
Robert Murphy*1, C Zala2, C Ochoa3, P Tharnish4, J Mathew4, E Fromentin5, G Asif5, S Hurwitz5, N Kivel4, and R Schinazi5
1Univ Pierre and Marie Curie, Paris, France; 2Hosp Privado Modelo, Buenos Aires, Argentina; 3ACLIRES-Argentina, Buenos Aires; 4RFS Pharma, LLC, Tucker, GA, US; and 5Emory Univ Sch of Med and VAMC, Atlanta, GA, US |
| 795 |
Vicriviroc in Combination Therapy with an Optimized ART Regimen for Treatment-experienced Subjects: VICTOR-E1
Barry Zingman*1, J Suleiman2, E DeJesus3, J Slim4, C Mak5, M McCarthy5, N Case5, and L Dunkle5
1Montefiore Med Ctr, Bronx, NY, US; 2Brazilmed Assistencia Medica e Pesquisa, Sao Paolo; 3Orlando Immunology Ctr, FL, US; 4St Michael`s Med Ctr, Newark, NJ, US; and 5Schering-Plough Res Inst, Kenilworth, NJ, US |
| 796 |
More Pronounced Effect of Integrase Inhibitor Raltegravir on Proviral DNA Reduction that other Antiretroviral Drugs in Patients Achieving Undetectable Viremia
Sari Arponen*, J Benito, S Lozano, F Blanco, C Garrido, C de Mendoza, J Gonzalez-Lahoz, and V Soriano
Hosp Carlos III, Madrid, Spain |
| 797 |
The Use and Response to Second Combination ART Regimens in EuroSIDA
Alessandro Cozzi-Lepri*1, M Cunnington2, A Lazzarin3, B Clotet4, B Knysz5, P Gargalianos6, C Katlama7, A Karlsson8, A Phillips1, J Lundgren9, and EuroSIDA Study Group
1Royal Free and Univ Coll Med Sch, London, UK; 2GlaxoSmithKline R&D, UK; 3San Raffaele Vita-Salute Univ, Milan, Italy; 4irsiCaixa Fndn and Lluita contra la SIDA Fndn, Badalona, Spain; 5Wrocaw Med Univ, Poland; 61st IKA Hosp, Athens, Greece; 7Hosp Pitie-Salpetriere, Paris, France; 8Karolinska Univ Hosp, Stockholm, Sweden; and 9Copenhagen HIV Prgm, Hvidovre, Denmark |
| 798 |
Long-term Consequences of the Delay between Virologic Failure of HAART and Regimen Modification: A Prospective Cohort Study
Maya Petersen*1, M van der Laan2, S Napravnik3, J Eron3, R Moore4, and S Deeks1
1Univ of California, San Francisco, US; 2Univ of California, Berkeley, US; 3Univ of North Carolina at Chapel Hill, US; and 4Johns Hopkins Univ, Baltimore, MD, US |
| 799 |
Outcomes of Patients Switched from Enfuvirtide to Raltegravir within a Virologically Suppressive Regimen
Marianne Harris*1, G Larsen1, and J Montaner2
1St Paul`s Hosp, Vancouver, Canada and 2BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada |
| 800 |
The Relationship of CCR5 Inhibitors to CD4 Cell Count Changes: A Meta-analysis of Recent Clinical Trials in Treatment-experienced Subjects
Timothy Wilkin*1, H Ribaudo2, and R Gulick1
1Weill Med Coll of Cornell Univ, New York, NY, US and 2Harvard Sch of Publ Hlth, Boston, MA, US |
|
